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Abstract
Objectives. Recurrent urinary tract infections are associated with
uropathogenic Escherichia coli (UPEC) ascending and infecting the
urinary tract. Antibiotics provide only symptomatic relief, not
prevent recurrence. Clinical evidence suggests that intravesical
glycosaminoglycan therapy, such as hyaluronic acid (HA), helps
reduce UTI recurrence. This has been investigated here using
in vitro systems modelling the urogenital tract tissues. Methods.
RT4 bladder cells were preconditioned with high molecular weight
HA (> 1500 kDa) at 2 mg mL1 and challenged with UPEC to
analyse barrier protection and bacterial adherence. Untreated and
HA-preconditioned VK2 E6/E7 vaginal cells were challenged with
E. coli flagellin (50 ng mL1) to mimic bacterial challenge, and
media analysed for lipocalin-2, human b-defensin 2 and
interleukin-8 by ELISA. Experiments were repeated after siRNA
knockdown of Toll-like receptors 2, 4 and 5, and CD44 to
investigate signalling. Results. Microscopic analyses showed
reduced bacterial adherence and urothelial disruption with HA,
suggesting that HA functions as a barrier protecting the
epithelium from bacterial infection. Cells treated with HA and
flagellin simultaneously produced more of the host antimicrobial
peptide LCN2 and pro-inflammatory IL-8 (P < 0.05) compared to
the no HA/flagellin challenges. Increased gene expression of
DEFB4 (P < 0.05), but not the hBD2 peptide, was observed in the
HA/flagellin-challenged cells. Conclusion. These data suggest that
exogenous HA has potential to protect the urogenital epithelia
from UPEC infection via a two-pronged approach that involves the
physical enhancement of the epithelial barrier and augmentation
of its innate immune response.
Keywords: host defence peptides, hyaluronic acid, innate
immunity, urinary tract infection, urothelial barrier.
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INTRODUCTION
Urinary tract infection (UTI) is one of the most
common bacterial infections with an estimated
150 million cases reported annually.1 Women are
particularly affected, with up to one-third of all
women and more than half of all postmenopausal
women suffering recurrence.2 Standard UTI
treatment is antibiotic therapy, but for patients
suffering from recurrent UTIs (rUTI), antibiotics
provide only a short period of symptomatic relief
before infection recurs. Moreover, the use of
prophylactic antibiotics to treat rUTI is
underpinning public health concerns about the
consequences of antibiotic resistance3 and driving
the need for alternative nonantibiotic
prophylactic options to treat rUTIs.4
In females, UTIs are caused when bacteria
originating in the gastrointestinal tract colonise
the vagina and peri-urethral area, and ascend to
the bladder where they cause infection.5 Such
organisms include Staphylococcus, Proteus,
Enterobacter, Klebsiella, Pseudomonas and
Enterococcus although the versatile pathogen
Escherichia coli, known specifically as
uropathogenic E. coli (UPEC), accounts for > 70%
of all infections.6 Innate mechanisms are key in
protecting the urinary tract from infection. These
include physical factors such as the flushing
action of urine which, together with its acid pH
and ionic composition, defend the urogenital
tract against bacterial colonisation and
adherence to the urothelium. Additionally, Toll-
like receptors (TLRs) located in the lower
urogenital tissues respond to microbe-associated
molecular patterns, specifically flagellin, and
trigger the release of host defence peptides as
well as inflammatory molecules that function to
clear potential UTIs.7,8 The importance of the
TLRs in defence of the urinary tract (UT) is
emphasised by studies where individuals carrying
the TLR5_C1174T (R392STOP) and TLR2_G2285A
(R753Q) SNP genotypes link to an increased risk
of infection.9–11
Postmenopausal women suffer more frequently
from UTIs,2 although the mechanisms controlling
their increased susceptibility are unclear. In the
vaginal tissues, oestrogen stimulates the
production of glycogen, which is metabolised by
the vaginal Lactobacilli populations to produce
lactic acid. It is proposed that the lactic acid
maintains an acid pH which helps to protect the
vaginal tissues from colonisation by potential
uropathogens including E. coli. Postmenopausal
women are characterised by reduced oestrogen
levels and those suffering rUTIs typically show a
vaginal pH above 4.5,12 suggesting that the
reduced oestrogen levels impact negatively on
Lactobacilli growth, which adversely affects the
vaginal microbiome.13–15 In support of a role for
oestrogen in the innate defence of the urogenital
tract, topical, but not oral oestrogen treatments
have proven successful in reducing infections with
these effects mediated through the vaginal
commensal populations and the urogenital innate
defences.16–19 However, because of the side
effects, the use of topical vaginal oestrogen is not
always appropriate for all women20 and hence its
therapeutic potential in treating rUTIs is limited.
Research for new therapeutic agents to help
treat rUTIs has focussed on understanding the
pathology of such infections, including
knowledge of the virulence factors utilised by
uropathogens to orchestrate an infection. UPEC
are characterised by pili that carry FimH adhesion
proteins that facilitate bacterial attachment
through binding of mannosylated receptors on
the urothelium. These structures are key to
infection and have been targeted in the
development of new therapeutics.21 However,
initial strategies employing a vaccine approach
and whole pili immunogens have proven
ineffective, and other methodologies including
the use of a FimC-FimH complex, UPEC toxins and
siderophores have reduced, but not totally
inhibited, UPEC infection of the bladder.22–24 In
contrast, agents called mannosides, which
function as FimH antagonists and reduce bacterial
attachment, show strong potential, with in vivo
approaches involving animal models
demonstrating the efficacy of a new class, the
C-mannosides.25 Recently, the FimH antagonist
M4284 when administered orally to mice has been
shown to reduce UPEC colonisation of the gut
microbiota.26 If proven clinically, this approach
will underpin an oral treatment available to all
those suffering rUTIs that functions by reducing
the faecal carriage of UPEC and hence the
incidence of UTIs. An alternative approach to
reduce UTI episodes in UTI-prone patients is the
deliberate inoculation of the bladder with a
nonadhering E. coli strain, 83972, to establish
asymptomatic bacteriuria.27 However, this
procedure involves catheterisation and is invasive
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for the patient and, while protective, reduces
rather than eliminates infections.
Other potential therapeutic agents include the
glycosaminoglycans (GAGs), hyaluronic acid (HA)
and chondroitin sulphate. Glycosaminoglycan
instillations when compared clinically to placebo
and antibiotics have been found to be linked to
fewer episodes of UTI recurrence in women and
longer periods between infections.28–30 Hence,
these agents appear protective against UTIs.
Again, however, clinical treatments involve an
invasive catheterisation procedure. More
acceptable therapeutically is a vaginal topical
agent applied by the rUTI patient that functions
as a barrier and prevents uropathogens from
colonising the vagina, and ascending via the
urethra to the bladder.11 To explore the potential
of HA as a topical treatment for rUTI, this study
used RT4 bladder and VK2E6/E7 vaginal cells to
model the urogenital tract in vitro. These cells
were preconditioned with HA and the effects of
an UPEC challenge on the epithelial barrier and
epithelial innate response examined using
imaging and host peptide gene expression and
protein analyses.
RESULTS
Hyaluronic acid and the urothelial barrier
Confluent urothelial cell monolayers cultured in
medium containing either HMW (1500–1800 kDa)
HA (2 mg mL1) or no HA were challenged with a
flagellated UPEC strain, TPA4935J, isolated from
the urine of a rUTI patient and modified to
express GFP. UPEC adherence to the unprotected
cell monolayer (no HA) was detected within 4 h
of infection, with the fluorescent bacteria locating
specifically to the tight junctions of the RT4 cell
monolayer and no visible adherence to other cell
surfaces (Figure 1a). Increasing bacterial
adherence was observed with incubation time,
and by 24 h, the urothelial cell monolayer was
severely disrupted. In contrast, bacterial
adherence was not observed in the cells treated
with HA until 6 h postinfection and the numbers
of adhering bacterial colonies were limited
(Figure 1a, Supplementary figure 1). At 24 h
post-UPEC infection, the monolayer of the
HA-treated cells remained intact, suggesting that
the HA was functioning as a barrier and
protecting the urothelium from bacterial
adherence, and hence infection.
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Figure 1. UPEC infection of urothelia. RT4 cells either alone or
preconditioned with hyaluronic acid (HA; 2 mg mL1) were exposed to
GFP-expressing UPEC (TPA4935J) for up to 24 h and microscopic images
captured. Cells were fixed and stained with phalloidin (red: actin
cytoskeleton) and DAPI (blue: nucleus) (a). RT4 cells with or without
hyaluronic acid (2 mg mL1) were assessed for paracellular flux of
fluorescein in presence of UPEC flagellin (50 ng mL1) or 105 bacteria
over a 60-min period (b). Data are mean  SEM (N = 3 experiments);
***P < 0.001. HAF, HA/Flagellin; B, Bacteria; HAB, HA/Bacteria.
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This barrier function was further supported by
paracellular flux measurements in which confluent
layers of bladder cells either preconditioned or
not with HA (2 mg mL1) were challenged with
either UPEC or flagellin, a key UPEC virulence
factor used to mimic infection. In the RT4 bladder
cells preconditioned with HA, the passive leak
of fluorescein (Figure 1b) and mannitol
(Supplementary figure 2) was reduced (P < 0.01)
compared to control. Moreover, flux was not
affected when the cells were challenged with
either UPEC or flagellin (F). However, in the
absence of HA and presence of UPEC, cell flux was
significantly increased compared to control
(P < 0.05; Figure 1b). These data strongly suggest
that the HA functions to tighten the epithelium
and enhance the physical integrity of the
epithelial monolayer.
Hyaluronic acid and the urothelial innate
response to UPEC flagellin
The innate response is pivotal in protecting the
urogenital tract from infection.7 Previous studies
have shown that incubating vaginal cells in vitro
with low molecular weight (LMW) HA (< 200 kDa)
elicits an innate immune response characterised by
the synthesis of host defence (HD) molecules,
including the defensins 1–3 and lactoferrin.31 In
contrast, treatment of vaginal VK2 E6/E7 and
bladder RT4 cells for 24 h with HMW HA did not
affect the expression of either the DEFB4 or LCN2
genes, encoding the host defence agents BD2 and
LCN2 (NGAL; Figure 2a and b). However,
challenging the HA-preconditioned cells for 24 h
with UPEC flagellin (50 ng mL1) significantly
enhanced gene expression (P < 0.01) compared to
flagellin alone. These data indicated that
preconditioning the urogenital cells with HMW HA
augmented the innate immune response of these
epithelia to flagellin, a key UPEC virulence factor.
If HA is to be considered for use as a vaginal
topical agent then the mechanisms regulating the
enhanced HA/flagellin signalling response require
elucidation. TLRs 2 and 4 and CD44 each represent
cell surface receptors of HA32 and the potential
roles of these receptors in enhancing the innate
response of the vaginal cells to flagellin, in the
presence of HA, was explored using a gene
knockdown approach (Supplementary figure 3).
The effects of silencing the TLR5 gene encoding
TLR5, which mediates the host response to
flagellin, were also examined.
Analyses of the VK2 E6/E7 vaginal cell media for
the host protein LCN2 following the HA/flagellin
challenge supported the gene expression data
(Figure 2b), with significantly elevated
concentrations of LCN protein (P < 0.01) compared
to flagellin alone (> 2 fold change) observed
(Figure 3a). These increases were not, however,
affected following the TLR2/4/CD44 gene
knockdowns. The BD2 protein concentrations in
media collected from flagellin-challenged cells also
increased (P < 0.05) compared to control. However,
the concentrations measured in the HA/flagellin-
challenged cells did not support augmentation of
the innate response (Figure 3b) with comparable
BD2 profiles observed in the media of the TLR2/4
and CD44 gene knockdown cells.
Measurement of the inflammatory protein
marker, IL-8, did not show significant protein
concentration changes in the media in response
to HA alone, suggesting that the HA treatment
was not associated with inflammatory effects in
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Figure 2. DEFB4 and LCN2 expression in cells preconditioned with
hyaluronic acid. Hyaluronic acid 1500–1800 kDa (2 mg mL1) was
applied to VK2 E6/E7 and RT4 cells and either PBS or flagellin
(50 ng mL1) added, the latter to simulate an UPEC infection for
up to 24 h. Gene expression of DEFB4 (a) and LCN2 (b) was
measured by qPCR. Data are mean  SEM (N = 3 experiments);
**P < 0.01, ***P < 0.001. F, Flagellin; HA, Hyaluronic acid; HAF,
HA/Flagellin.
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the vaginal cells (Figure 3c). This observation was
also supported by the lack of increase in IL1b
gene expression (Supplementary figure 4).
Significantly increased IL-8 concentrations were
observed when the cells were challenged with
E. coli flagellin and these were also enhanced
(P < 0.05) in the presence of HA. Augmentation of
the IL-8 protein response was similarly observed in
all the knockdown experiments although these
data suggested the involvement of TLR2/4.
Following TLR5 knockdown, reduced
concentrations of LCN and IL8 were detected in the
media following flagellin challenge (Figure 4a and
c), but augmentation of the response was still
observed in the challenged cells pretreated with
HA compared to flagellin alone. In contrast,
flagellin treatment of the TLR5 gene knockdown
cells was associated with an increased BD2 response
compared to the control siRNA cells. HA/flagellin
treatment of such cells followed a similar pattern,
but the presence of HA was not associated with an
augmented response (Figure 4b).
Hyaluronic acid and NFjB signalling
The transcription factor NFjB is a key signalling
molecule functioning in the innate response of
the urogenital cells to flagellin11 and the response
to HA.33 The signalling responses of VK2 E6/E7
and RT4 cells are comparable in their NFjB
response to flagellin11; therefore, to further
explore the signalling mechanisms underpinning
the HA/flagellin effects, urothelial cells stably
engineered to contain an NFjB reporter were
used. These cells were incubated with flagellin (F),
HMWT HA, HA/flagellin (HAF), heat-killed UPEC
(TPA4935) (B) and HA/B, and NFjB signalling
measured from one to 24 h following challenge
(Figure 5). HMWT HA treatment alone did not
induce NFjB activity up to 24 h, supporting its
noninflammatory properties. By 3 h of flagellin
treatment NFjB signalling was evident, although
no response was observed in the flagellin-treated
cells preconditioned with HA, supporting it
functioning as a protective barrier. At 6 h, NFjB
activity was detected in the HA/flagellin-treated
cells, but at a reduced level (P < 0.05) compared
to the cells treated with flagellin alone. The NFjB
signalling response to the HA/B-challenged cells
remained comparable to control levels for up to
24 h. These data were consistent with the HA
forming a protective layer and helping to protect
the epithelium from whole bacteria and flagellin
proteins.
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Figure 3. IL-8, BD2 and LCN2 measurements following TLR2/4 and CD44 receptor gene knockdowns. VK2 cells were subjected to siRNA control
knockdown (black bars), TLR2&4 together (dark grey bars) or CD44R knockdown (light grey bars). After 48 h, cells were incubated for 24 h plus/
minus hyaluronic acid and challenged with flagellin (50 ng mL1). Media postchallenge was collected, and LCN2 (a), BD2 (b) and IL-8 (c)
concentrations were measured by ELISA, and data presented as fold change. Data are mean  SEM (N = 2 experiments, n = 6 technical
replicates); *P < 0.05, **P < 0.01, ***P < 0.001. C, Control; F, Flagellin; HA, Hyaluronic acid; HAF, HA/Flagellin.
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DISCUSSION
The glycosaminoglycan HA is found naturally
throughout the body as a major constituent of
the extracellular matrix,34 and functions in
healthy tissues to regulate cell growth,
differentiation and to inhibit inflammation.32
Clinically, bladder instillations containing HA have
been shown to reduce UTI episodes and
pain30,35,36 with in vivo studies suggesting that HA
treatment is associated with reduced bacterial
growth.37 However, these are only used in cases
of extremely unresponsive rUTIs.20 A recent
clinical trial has reported the effects of HA
combined with Propionibacterium acnes as a
potential treatment to combat vaginal infections,
functioning presumably by enhancing the immune
system in the vaginal/vulval tissues.38 While this
therapy did reduce the symptoms of bacterial
vaginosis, the study lacked a control arm treated
with HA alone, hence the actual contribution of
HA cannot be ascertained. Although the literature
reporting the vaginal use of HA as a topical agent
to treat UTI incidence in vivo, either through
clinical human trials or animal studies, is sparse
the evidence to date does support a role for HA
in protecting the urogenital tract from infection.
To further explore the mechanisms by which HA
helps protect from UTI an in vitro approach
exploiting RT4 and VK2 E6/E7 cells, modelling the
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Figure 5. NFkB signalling in cells preconditioned with hyaluronic acid
and challenged with UPEC or flagellin. HA and RT4 cells expressing an
NFkB luciferase reporter gene were challenged with HA (2 mg mL1),
F (50 ng mL1) or heat-killed UPEC (104 per well) for up to 24 h.
Cells were subsequently lysed, luciferase substrate added and the
resulting luminescence recorded. Data are mean  SEM (N = 3
experiments, *P < 0.05, ***P < 0.001). C, Control; HA, Hyaluronic
acid; F, Flagellin; HAF, HA/Flagellin; B, Bacteria; HAB, HA/Bacteria.
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urogenital tract tissues, was used. Cells challenged
with UPEC resulted in bacteria being localised to
the tight junctions of the urothelium, which over
24 h resulted in a weakened, disrupted epithelial
barrier concomitant with UTI pathology. These
data endorsed previous observations,39–41 and
supported an UPEC infection mechanism involving
manipulation of the paracellular pathway. Tight
junction investigation in primary urothelial cells
has shown that claudin 3, ZO-1 and ZO-1a+ are
important for the correct functionality of tight
junctions in urothelia,42,43 with the loss of ZO-1
associated with UPEC infection of bladder
epithelia39 and a potential UPEC target.
Preconditioning the cells with HA reduced
bacterial attachment and epithelial disruption,
which supported the glycosaminoglycan as
protecting the epithelial barrier physically.
Although the cell line model does not take into
account urinary flushing and hence potential loss
of the HA layer, it does demonstrate the positive
effects of using HA to help protect the urogenital
tract from infection. Clinically, we suggest using
HA as a topical vaginal treatment rather than a
bladder treatment, hence we predict that any
flushing effects would be reduced. One method
by which UPEC has been reported to infect the
murine urinary tract is through attaching to CD44
receptors44 that also bind HA.45 Although
receptor masking by HMW HA may have
functioned in reducing UPEC infection in vivo,
specific localisation of UPEC to the epithelial tight
junctions was less supportive of such a mechanism
operating in the human urothelial cell model.
High molecular weight hyaluronic acid has been
shown to protect against inflammation, and the
mechanism is suggested to involve cross-linking of
the glycosaminoglycan with transmembrane CD44
receptors.32 The importance of the cell adhesion
receptor molecule CD44 in this process has been
further demonstrated in vivo using CD44/ mice,
with the accumulation of LMW HA associated with
and responsible for an exaggerated inflammatory
response.46,47 Consistent with the reported
properties of HMW HA, its application to urothelial
cells was not associated with inflammation as
measured by either NFjB signalling or immune
effector synthesis. Interestingly, however, the
presence of exogenous HMW HA enhanced the
innate response of the urogenital cells to E. coli
flagellin, a virulence factor used in vitro to mimic
an UPEC infection. Bacterial infection and cell
injury are associated with hyaluronidase activity48
and the accumulation of LMW material. Moreover,
the inappropriate clearance and persistence of LMW
HA links to multiple inflammatory pathologies
including arthritis, lung fibrosis49 and potentially
interstitial cystitis.50 While the lack of innate
responses to the HMW material alone suggested no
contamination with LMW material, it cannot be
excluded the endogenous production of LMW HA
during the challenge period was responsible for the
enhanced effector responses. LMW HA has been
reported to function through TLRs 2 and 4, but
independently of CD44, to stimulate the synthesis of
host defence effectors including BD2 and SLPI in
vaginal cells.31 Surprisingly, however, in view of its
pro-inflammatory properties,32 these responses
observed using the VK2E6/E7 cell model were
reported to be independent of pro-inflammatory
cytokine production.
The actual signalling mechanisms regulating the
augmented urothelial innate response to
HA/flagellin in our in vitro challenges remain
uncertain. Our data, as predicted, supported a
role for TLR5 but it did not strongly support
either TLR2/4 or CD44 involvement. It cannot be
excluded, however, that these data were
prejudiced by the signalling activities of receptors
persisting following incomplete gene knockdown.
HMW HA treatment is not only associated with
receptor binding but also receptor clustering that
functions, potentially, to stabilise cell membrane
transporters and/or receptors.45 Hence, if activated
urothelial TLR5 and CD44 receptors cluster
similarly in response to flagellin and HA, then the
outcome supports signal amplification through
either better retention of their respective ligands
or increased rebinding. While the mechanisms
underpinning signal amplification remain obscure,
cooperation between receptors either physically
or through shared intracellular signalling
molecules cannot be excluded. The potential roles
of other HA binding molecules such as the
hyaladherins, RHAMM, LYVE-1 and HARE32 also
remain to be explored.
In contrast to LCN2 and IL-8, it was surprising
that no enhancement of the BD2 peptide
response was observed in the presence of either
flagellin or HA/flagellin, an observation that did
not marry with the DEFB4 expression data. BD2
peptide molecules are positively charged and have
been reported to bind to negatively charged
GAGs.51 It is therefore possible that precipitation
of the BD2-GAG complexes on the epithelial cell
surface masked the in vitro increase in BD2
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concentrations in response to flagellin. However,
these data were further complicated by the
enhanced BD2 responses following TLR5 gene
knockdown. Such observations may have reflected
the responses of the cells to reduced TLR5
numbers including the recycling of endocytosed
TLR5 receptors to the cell membrane, the
unregulated release of BD2 from intracellular cell
granules or other negative feedback mechanisms
functioning to increase the synthesis and storage
of BD2. As BD2 is a key effector in defending the
urogenital tract11 and the enhanced responses
appeared independent of NFjB signalling, further
investigation of this response is required.
Overall, these in vitro data provide evidence for
HMW HA functioning not only as a mechanistic
barrier protecting the urothelium from UPEC
infection, but also boosting the innate response
of the epithelium in the presence of flagella, a
key UPEC virulence factor. These two protective
mechanisms, while independent, support previous
in vivo observations reported using rodents37,52 as
well as complementing each other to limit
bacterial growth. They also help to explain why
HA instillations, clinically, are successful in
reducing UTI episodes.30 These observations also
suggest that therapeutic topical HA has potential
as an alternative or co-treatment to antibiotics in
the management of recurrent UTIs. However,
focussed clinical trials are required to underpin its
therapeutic use as a topical agent.
METHODS
Cell culture
Vaginal and bladder epithelia were modelled using VK-2
E6/E7 (ATCC-CRL2616) and RT-4 (ATCC-HTB-2) cells
respectively. VK2 cells, cultured in Keratinocyte-SFM
(ThermoFisher) with recommended supplements, were
seeded into 12-well plates (2 9 105 cells per well). RT4 cells,
cultured in RPMI with L-glutamine (2 mM), HEPES (2.5%)
and 10% FBS (Sigma), were seeded into 6-well plates
(5 9 105 cells per well), or 12-well transwells (1.2 9 105 cells
per well). RT4 with NFkB luciferase reporter plasmid53 were
grown in RT4 media with G418 (0.5 mg mL1) and seeded
into 96-well plates (5 9 104 cells per well).
Mimicking bacterial infection
Confluent vaginal or bladder cells were incubated with HA
MW 1500–1800 kDa (Sigma; 0.2%, 2 mg mL1) and UPEC
flagellin (F) (50 ng mL1)11 alone or together for up to
24 h. Media was collected for ELISA analyses and cells lysed
for RNA extraction and qPCR.
Epithelial flux
RT4 cells were grown on transwells for 14 days, followed by
1-h incubation with HA (2 mg mL1) and 6-h challenge with
either clinical UPEC isolate, 3412, (105–107 cells per mL) or
flagellin (50 ng mL1). To test whether HA protected the
epithelial barrier, 14C-mannitol (10 lM) or fluorescein
(100 lg mL1) was added to the apical compartment and
media sampled from the basolateral compartment at time
periods up to 1 h. Radiolabelled mannitol was detected
using a scintillation counter and fluorescence measured
using a FluoStar Omega microplate reader (BMG Labtech,
Ortenberg, Germany).
Luciferase assay
RT4 cells stably transfected with NFKB luciferase reporter
plasmid53 were challenged for up to 24 h with either
flagellin (50 ng mL1) or heat-killed UPEC (104 per well).
Cells were lysed overnight at 80°C with reporter lysis
buffer (Promega) and luciferase activity measured using a
luciferase reporter assay kit (Promega). Luminescence was
measured using the FLuostar Omega plate reader.
Staining and imaging of cells
RT4 cells were seeded onto 8-well chamber slides (Corning)
at 3 9 104 cells per well and grown to confluence. Cells
either preconditioned or not with HA (2 mg mL1) were
challenged for up to 24 h with TPA4935J, a clinical UPEC
isolate transformed with pEGFp-C3 (102 per well). After
washing with PBS, fixing in 4% PFA the cells were stained
for 2 h with CytoPainter Phalloidin-iFluor 594 reagent
(Abcam) diluted 1:1000, and coverslips mounted using
Vectasheild with DAPI (Vector Laboratories). Images were
captured using a Leica SP8 confocal microscope
(fluorescence) or an EVOS XL Core Cell Imaging System
(Thermo Fisher; light microscope images). Image analysis
was conducted using LAS X (Leica) and Image J software.
siRNA Knockdowns
Transfection of VK2 cells with siRNA (ThermoFisher) was
performed using Viromer Green (Lipocalyx) at 65%
confluence. siRNAs used were as follows: s168 (TLR2),
s14196 (TLR4), s2681 (CD44), s14199 (TLR5), AM4611
(negative siRNA 1). Transfection was performed at 90.5
reaction volume (single knockdown) or 90.25 reaction
volume (double knockdown) following the manufacturer’s
protocol for 48 h, followed by challenge with HA and/or
flagellin as previously described for 24 h.
RNA extraction and qPCR
RNA extraction used the SV Total RNA Isolation Kit
(Promega), and nucleic acid was quantified by nanodrop.
Reverse transcription of RNA (400 ng) used random
hexamers (Roche), MMLV Reverse Transcriptase and RNase
Inhibitor (Promega). mRNA expression was quantified by
qPCR using SYBR Green (Roche) with 0.5 lM primers on a
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LightCycler 480 (Roche). Appropriate reference genes,
GAPDH and ATP5b for VK2, GAPDH for RT4, were
determined using GeNorm54 (Primer Design). Primer
sequences of target genes can be found in Supplementary
table 1. PCR products were verified by sequencing and
controls were included in each plate, enabling verification
of single target amplification using melt curve
analysis. Data were normalised to the appropriate
reference genes.
ELISA
ELISA kits to measure protein levels of BD2 (Leinco
Technologies), lipocalin-2 (LCN2) and interleukin-8 (IL-8;
both R&D Systems) in media harvested from cell challenges
were used as per manufacturer’s instructions. Absorbance
was measured at 540 and 450 nm using a FLUOstar Omega
(BMG Labtech, Germany) plate reader, with a standard
curve and negative control on each plate.
Statistical analyses
Data are presented as mean  SEM, and statistical analyses
were performed using the Prism 6 Software package
(GraphPad Software Inc, La Jolla, California, USA).
For analyses of data involving more than two groups,
a one-way analysis of variance followed by a Bonferroni
post-test at a significance level of P < 0.05 was used.
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